Noxafil (posaconazole) delayed-release tablets — Highmark
Treatment of invasive aspergillosis infection
Preferred products
- voriconazole
- generic posaconazole delayed-release tablets
Initial criteria
- Member is age ≥ 13 years
- Diagnosis of invasive aspergillosis infection
- Member has experienced therapeutic failure, contraindication, or intolerance to voriconazole
- If brand Noxafil delayed-release tablets requested, member has experienced therapeutic failure or intolerance to generic posaconazole delayed-release tablets
Reauthorization criteria
- Prescriber attests that the member has experienced positive clinical response to therapy
Approval duration
12 months